Diabetes Medicines are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.
The global Diabetes Medicines market was valued at US$ 97410 million in 2023 and is anticipated to reach US$ 207020 million by 2030, witnessing a CAGR of 11.2% during the forecast period 2024-2030.
Global Diabetes Medicines key players include Novo Nordisk, Sanofi, Eli Lilly, Merck & Co, Boehringer Ingelheim, etc. Global top five manufacturers hold a share over 62%.
In terms of product type, Injection is the largest segment, with a share of 60%. And in terms of application, Hospital has a share about 67 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Diabetes Medicines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetes Medicines.
The Diabetes Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Diabetes Medicines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetes Medicines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Conker Pharmaceuticals
Jiangsu Wanbang
Geropharm
Wockhardt
Merck Serono
Novartis
Segment by Type
Oral
Injection
Segment by Application
Hospital
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Diabetes Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Diabetes Medicines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Diabetes Medicines Market Overview
1.1 Product Definition
1.2 Diabetes Medicines by Type
1.2.1 Global Diabetes Medicines Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Injection
1.3 Diabetes Medicines by Application
1.3.1 Global Diabetes Medicines Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Diabetes Medicines Market Size Estimates and Forecasts
1.4.1 Global Diabetes Medicines Revenue 2019-2030
1.4.2 Global Diabetes Medicines Sales 2019-2030
1.4.3 Global Diabetes Medicines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Diabetes Medicines Market Competition by Manufacturers
2.1 Global Diabetes Medicines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Diabetes Medicines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Diabetes Medicines Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Diabetes Medicines, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Diabetes Medicines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Diabetes Medicines, Product Type & Application
2.7 Global Key Manufacturers of Diabetes Medicines, Date of Enter into This Industry
2.8 Global Diabetes Medicines Market Competitive Situation and Trends
2.8.1 Global Diabetes Medicines Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Diabetes Medicines Players Market Share by Revenue
2.8.3 Global Diabetes Medicines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Diabetes Medicines Market Scenario by Region
3.1 Global Diabetes Medicines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Diabetes Medicines Sales by Region: 2019-2030
3.2.1 Global Diabetes Medicines Sales by Region: 2019-2024
3.2.2 Global Diabetes Medicines Sales by Region: 2025-2030
3.3 Global Diabetes Medicines Revenue by Region: 2019-2030
3.3.1 Global Diabetes Medicines Revenue by Region: 2019-2024
3.3.2 Global Diabetes Medicines Revenue by Region: 2025-2030
3.4 North America Diabetes Medicines Market Facts & Figures by Country
3.4.1 North America Diabetes Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Diabetes Medicines Sales by Country (2019-2030)
3.4.3 North America Diabetes Medicines Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Diabetes Medicines Market Facts & Figures by Country
3.5.1 Europe Diabetes Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Diabetes Medicines Sales by Country (2019-2030)
3.5.3 Europe Diabetes Medicines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diabetes Medicines Market Facts & Figures by Region
3.6.1 Asia Pacific Diabetes Medicines Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Diabetes Medicines Sales by Region (2019-2030)
3.6.3 Asia Pacific Diabetes Medicines Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Diabetes Medicines Market Facts & Figures by Country
3.7.1 Latin America Diabetes Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Diabetes Medicines Sales by Country (2019-2030)
3.7.3 Latin America Diabetes Medicines Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Diabetes Medicines Market Facts & Figures by Country
3.8.1 Middle East and Africa Diabetes Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Diabetes Medicines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Diabetes Medicines Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Diabetes Medicines Sales by Type (2019-2030)
4.1.1 Global Diabetes Medicines Sales by Type (2019-2024)
4.1.2 Global Diabetes Medicines Sales by Type (2025-2030)
4.1.3 Global Diabetes Medicines Sales Market Share by Type (2019-2030)
4.2 Global Diabetes Medicines Revenue by Type (2019-2030)
4.2.1 Global Diabetes Medicines Revenue by Type (2019-2024)
4.2.2 Global Diabetes Medicines Revenue by Type (2025-2030)
4.2.3 Global Diabetes Medicines Revenue Market Share by Type (2019-2030)
4.3 Global Diabetes Medicines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Diabetes Medicines Sales by Application (2019-2030)
5.1.1 Global Diabetes Medicines Sales by Application (2019-2024)
5.1.2 Global Diabetes Medicines Sales by Application (2025-2030)
5.1.3 Global Diabetes Medicines Sales Market Share by Application (2019-2030)
5.2 Global Diabetes Medicines Revenue by Application (2019-2030)
5.2.1 Global Diabetes Medicines Revenue by Application (2019-2024)
5.2.2 Global Diabetes Medicines Revenue by Application (2025-2030)
5.2.3 Global Diabetes Medicines Revenue Market Share by Application (2019-2030)
5.3 Global Diabetes Medicines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Diabetes Medicines Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Diabetes Medicines Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly Diabetes Medicines Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Diabetes Medicines Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 AstraZeneca Diabetes Medicines Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 bayer
6.6.1 bayer Company Information
6.6.2 bayer Description and Business Overview
6.6.3 bayer Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 bayer Diabetes Medicines Product Portfolio
6.6.5 bayer Recent Developments/Updates
6.7 Boehringer Ingelheim
6.7.1 Boehringer Ingelheim Company Information
6.7.2 Boehringer Ingelheim Description and Business Overview
6.7.3 Boehringer Ingelheim Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Boehringer Ingelheim Diabetes Medicines Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Johnson & Johnson
6.8.1 Johnson & Johnson Company Information
6.8.2 Johnson & Johnson Description and Business Overview
6.8.3 Johnson & Johnson Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Johnson & Johnson Diabetes Medicines Product Portfolio
6.8.5 Johnson & Johnson Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Company Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Takeda Diabetes Medicines Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 Tonghua Dongbao
6.10.1 Tonghua Dongbao Company Information
6.10.2 Tonghua Dongbao Description and Business Overview
6.10.3 Tonghua Dongbao Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tonghua Dongbao Diabetes Medicines Product Portfolio
6.10.5 Tonghua Dongbao Recent Developments/Updates
6.11 United Pharmaceuticals
6.11.1 United Pharmaceuticals Company Information
6.11.2 United Pharmaceuticals Description and Business Overview
6.11.3 United Pharmaceuticals Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 United Pharmaceuticals Diabetes Medicines Product Portfolio
6.11.5 United Pharmaceuticals Recent Developments/Updates
6.12 Ganli Pharmaceutical
6.12.1 Ganli Pharmaceutical Company Information
6.12.2 Ganli Pharmaceutical Description and Business Overview
6.12.3 Ganli Pharmaceutical Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Ganli Pharmaceutical Diabetes Medicines Product Portfolio
6.12.5 Ganli Pharmaceutical Recent Developments/Updates
6.13 Biocon
6.13.1 Biocon Company Information
6.13.2 Biocon Description and Business Overview
6.13.3 Biocon Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Biocon Diabetes Medicines Product Portfolio
6.13.5 Biocon Recent Developments/Updates
6.14 Conker Pharmaceuticals
6.14.1 Conker Pharmaceuticals Company Information
6.14.2 Conker Pharmaceuticals Description and Business Overview
6.14.3 Conker Pharmaceuticals Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Conker Pharmaceuticals Diabetes Medicines Product Portfolio
6.14.5 Conker Pharmaceuticals Recent Developments/Updates
6.15 Jiangsu Wanbang
6.15.1 Jiangsu Wanbang Company Information
6.15.2 Jiangsu Wanbang Description and Business Overview
6.15.3 Jiangsu Wanbang Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Jiangsu Wanbang Diabetes Medicines Product Portfolio
6.15.5 Jiangsu Wanbang Recent Developments/Updates
6.16 Geropharm
6.16.1 Geropharm Company Information
6.16.2 Geropharm Description and Business Overview
6.16.3 Geropharm Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Geropharm Diabetes Medicines Product Portfolio
6.16.5 Geropharm Recent Developments/Updates
6.17 Wockhardt
6.17.1 Wockhardt Company Information
6.17.2 Wockhardt Description and Business Overview
6.17.3 Wockhardt Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Wockhardt Diabetes Medicines Product Portfolio
6.17.5 Wockhardt Recent Developments/Updates
6.18 Merck Serono
6.18.1 Merck Serono Company Information
6.18.2 Merck Serono Description and Business Overview
6.18.3 Merck Serono Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Merck Serono Diabetes Medicines Product Portfolio
6.18.5 Merck Serono Recent Developments/Updates
6.19 Novartis
6.19.1 Novartis Company Information
6.19.2 Novartis Description and Business Overview
6.19.3 Novartis Diabetes Medicines Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Novartis Diabetes Medicines Product Portfolio
6.19.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diabetes Medicines Industry Chain Analysis
7.2 Diabetes Medicines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diabetes Medicines Production Mode & Process
7.4 Diabetes Medicines Sales and Marketing
7.4.1 Diabetes Medicines Sales Channels
7.4.2 Diabetes Medicines Distributors
7.5 Diabetes Medicines Customers
8 Diabetes Medicines Market Dynamics
8.1 Diabetes Medicines Industry Trends
8.2 Diabetes Medicines Market Drivers
8.3 Diabetes Medicines Market Challenges
8.4 Diabetes Medicines Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Conker Pharmaceuticals
Jiangsu Wanbang
Geropharm
Wockhardt
Merck Serono
Novartis
*If Applicable.